Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences, a clinical-stage biotechnology company focused on developing a novel therapy for ocular cancers, announced its CEO, Natalie Holles, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. The company highlighted its Phase 3 fully enrolled trial for bel-sar in early choroidal melanoma and ongoing studies in…